GSK plc (NYSE:GSK) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in GSK plc (NYSE:GSK) by 10.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,094,105 shares of the pharmaceutical company’s stock after buying an additional 190,047 shares during the period. Wellington Management Group LLP’s holdings in GSK were worth $70,823,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Primecap Management Co. CA raised its holdings in GSK by 70.1% in the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after acquiring an additional 10,407,905 shares during the last quarter. Mondrian Investment Partners LTD increased its holdings in shares of GSK by 17.6% in the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after purchasing an additional 874,004 shares during the last quarter. Miller Howard Investments Inc. NY purchased a new position in GSK during the fourth quarter worth approximately $23,366,000. Equity Investment Corp boosted its stake in GSK by 13.3% during the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after buying an additional 466,327 shares during the last quarter. Finally, Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD purchased a new stake in GSK in the 4th quarter valued at $11,584,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK stock opened at $36.49 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a fifty day simple moving average of $37.63 and a 200-day simple moving average of $36.59. The stock has a market cap of $75.53 billion, a P/E ratio of 22.95, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.31%. The ex-dividend date is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.